The ontogenesis of pancreatic thyrotropin-releasing hormone (TRH) 
Introduction
Recently thyrotropin-releasing hormone (TRH),' a neuropeptide first detected in hypothalami and cerebral tissues (see ref. 1 for review), has also been found in the pancreas (2, 3). There is compelling evidence that TRH is located in the islets of Langerhans (4, 5), and more specifically within the B cells producing insulin (6-8). Somewhat surprisingly, in the rat, a high TRH content has been detected on prenatal day 21 (9), reaching a peak on postnatal days 2-3 and decreasing thereafter (10-13). Similarly, TRH-immunoreactive cells are most numerous in the early neonatal period; their number decreases later from day 8 onward (7). Large amounts ofTRH have been identified in pancreatic tissues of human neonates (14) , rapidly falling to adult levels (15). A similar pattern of development is thus speculated in humans.
However, to our knowledge, there is no information regarding the ontogenesis of pancreatic TRH in the human fetus. The present study was performed with the intent of identifying the gestational time of appearance and the distribution of TRH. The possibility that TRH may be present in the human fetal pancreas was examined with the methodology (immunocyto-chemistry and radioimmunoassay) successfully employed to localize this peptide in normal (13) , hypothyroid (16, 17) , and streptozotocin-treated newborn (8) rat pancreas. In an effort to clarify the ultrastructural localization of TRH, we also pursued at the ultrastructural level the identification of the immunoreactive cell populations initially investigated by light microscopy (18-21).
Methods
Our study was carried out according to guidelines established by the National Ethical Committee. Human fetuses were obtained after legal abortions. Gestational age was carefully determined by the crown-rump length (22) .
Materials. Pancreatic TRH was measured by radioimmunoassay from (a) 22 normal fetuses age 6-20 wk (Table I) , and (b) two anencephalic female fetuses (26 and 32 wk old). To gain more information about TRH topography, we also studied a particular anatomical region of the pancreas (i.e., the lower posterior part of the head) from three normal fetuses age 13-15 wk (Table I ances of the independent groups could not be assumed to be equal, the Kruskal-Wallis one-way analysis of variance by ranks was employed to test the ontogenetic development of TRH (28) . The null hypothesis is that the independent values of three age groups (6-8 wk, 9-12 wk, and 13-20 wk) come from the same continuous population. Similarly, the Mann-Whitney U test was used to test the TRH topography in two major anatomical regions of the pancreas (28) . The null hypothesis is that the independent values oftwo tissue groups (i.e., the lower posterior part ofthe head and the body) represent a distribution that has underlying continuity.
Histological preparations. Location of pancreatic TRH was studied in sections that were fixed in 4% p-formaldehyde and 0.5% glutaraldehyde for 2 h and postfixed in 1% osmium tetroxide for 1 h at 4VC. Some of the tissue was only fixed in 1% osmium tetroxide for 2 h or 4% p-formaldehyde for 6 h. After embedding in Araldite, semithin and thin sections were cut on an Ultrotome III (LKB Instruments, Inc., Bromma, Sweden), and stained immunocytochemically. Semithin sections were previously deresinated in a saturated solution of sodium hydroxide in methanol, and treated with 1-5% periodic acid (17) . Thin sections were pretreated with sodium metaperiodate (17) . We also used the pancreas of 5-24-wk-old human fetuses previously fixed in Bouin-Hollande sublimate and embedded in paraffin wax (23) . Paraffin sections were deparaffinjzed in toluene and processed for immunocytochemistry.
Light microscopic immunocytochemistry. Semithin and paraffin sections were processed at room temperature in a humid chamber by the indirect immunoperoxidase method of Nakane and Pierce (29) , with some modifications (17) . The primary anti-hormone sera included anti-TRH (1:2,000; No. IS4B1 1, a gift from Dr. D. Grouselle and Dr. A.
Tixier-Vidal, College de France, Paris, France); anti-insulin (1:5,000, No. 24-2), and anti-COOH-terminal glucagon (1:2,500, No. GB 5667) (a gift from Dr. R. Assan, Hopital Bichat, Paris, France); and anti-somatostatin (1:1,000, No. 19608, a gift from Dr. M. P. Dubois, Nouzilly, France). All anti-hormone sera were raised in rabbits. Goat anti-rabbit immunoglobulin G conjugated to peroxidase was purchased from Nordic Immunology (London).
Electron microscopic immunocytochemistry. The immunocytochemical reaction on thin sections with the peroxidase-antiperoxidase complex (30) was based on the method described by Moriarty and Halmi (31) . Peroxidase-antiperoxidase complex (the antiperoxidase made in rabbit) was purchased from Dako-immunoglobulins a/s (Copenhagen, Denmark).
Anti-hormone sera specificity tests. The anti-hormone sera have been thoroughly tested and described in detail elsewhere (17) (18) (19) (20) (21) 32) . Nevertheless, the immunocytochemical controls were repeated for this study. The specificity ofthe staining was confirmed by demonstrating complete blockade ofthe positive reaction in the sections when they were incubated with anti-TRH serum depleted of anti-TRH reactivity by treatment with a solid-phase TRH immunoabsorbent. Technical details were described elsewhere (17) . Furthermore, absorption ofthe anti-TRH serum with pancreatic (insulin, proinsulin C peptide, glucagon, glicentin, somatostatin, pancreatic polypeptide) and brain (gonadoliberin, lysine-vasopressin, oxytocin, a-melanocyte-stimulating hormone, prolactin, corticotropin-releasing factor) hormones or hormone fragments (TRH free acid, p-Glu-His OH, Glu-His OH, His-Pro-Diketopiperazine) had no effect on immunostaining. To eliminate the immunoreaction with the anti-insulin, anti-glucagon, or anti-somatostatin serum, addition of 15 nmol insulin, 55 nmol glucagon, and 225 nmol somatostatin were necessary, respectively. To prevent labeling of islet cells by electrostatic and hydrophobic binding of immunocytochemical reagents with tissue or by cross-reacting antibodies (33, 34) , all anti-hormone sera were used at high dilutions (as indicated above).
Morphometry. A mean granule profile diameter per cell type was computed from measurements taken from standard enlargements of the electron micrographs. It was estimated with the aid of an image analyzer (Kontron Analytical, Everett, MA) after drawing the outlines of secretory granules. The mean values (in nanometers) of granule profile diameter were characterized with the aid of the 95% confidence limits (mean±1.96 SD/IV).
Results

TRH radioimmunoassay.
As shown in Table I to 12 wk and remained low thereafter (96.1±28.9 between 13 and 20 wk). The Kruskal-Wallis test revealed that the TRH concentrations were not the same in the three age groups, since the TRH concentration was highest in the 6-8-wk group, intermediate in the 9-12-wk group, and was lowest in the 1 3-20-wk group (H . 10.31; P < 0.01). We conclude that the specified
The same cell population (arrows) is positive for both TRH and insulin. In addition, the TRH immunoreactive cells are distinct from glucagon-containing cells or somatostatin-containing cells.
three age groups differ in the TRH content. In contrast, the Mann-Whitney U test revealed that the TRH concentrations were the same in the lower posterior part of the head (111.2±23.2) and the body (96.1±28.9) between 13 and 20 wk (Table I) . Indeed, we see that U < 7 has a probability of occurrence of P = 0.258. Thus, the data support the null hypothesis. 
Immunocytochemistry of TRH
Comparison offixatives. Of the procedures for tissue preparation tested, only a mixture of p-formaldehyde and glutaraldehyde followed by a secondary fixation with osmium tetroxide were successful for detecting TRH immunoreactivity in the human fetal pancreas (Fig. 1, A and B) . In contrast, the anti-islet hormone (insulin, glucagon, and somatostatin) sera gave positive immunostaining whatever the fixation procedures. Unfortunately, preliminary light microscopic studies revealed that the antigenicity of TRH was destroyed by the fixation with BouinHollande sublimate. Consequently, pancreatic fragments previously collected from 48 5-24-wk-old human fetuses (23) could not be used.
Location of TRH-immunoreactive cells. At the light microscope level, intense TRH immunoreactivity was observed between 12 and 19 wk of gestation in the pancreatic parenchyma. The staining was confined to the islet cell clusters at the 12th week ( Fig. 1 A) , and to the typical islets from the end of the fourth month (Fig. 1 B) . The TRH-immunoreactive cells tended to accumulate in the central portion of each islet, and were surrounded by a rim of unstained cells (Fig. 1 B) . The reaction product was present in all the pancreatic islets of the male and female fetuses investigated. The exocrine tissue ofthe fetal pancreas was unstained. Also, no nerve cells or fibers within the pancreas contained TRH-immunoreactivity.
Topographical relation of TRH with other islet hormones. In the light microscopic-immunocytochemical study, we confirmed the pattern ofdevelopment ofinsulin immunoreactivity, glucagon immunoreactivity, and somatostatin immunoreactivity. As previously reported (18-21), immunoreactive cells were interspersed among the islet cell clusters at the 12th week of gestation, and still later ( 16 wk) inside the recognizable islets of Langerhans. At this stage, insulin immunoreactivity was observed in the central portion of the islets while glucagon immunoreactivity and somatostatin immunoreactivity were confined to the peripheral parts (Fig. 2, B, D, and F) . In the electron microscopic-immunocytochemical study, all morphological features of the various cells revealed by conventional electron microscopy ( Fig. 3) were recognized after the immunocytochemical reaction (Fig. 4) .
When semithin sections adjacent to those processed with the anti-TRH serum were incubated with the anti-insulin serum, it was observed that both anti-hormone sera stained the same population of endocrine cells (Fig. 2, A and B) . In contrast, the TRH-immunoreactive cells were distinct from glucagon-containing cells or somatostatin-containing cells (Fig. 2, C-F identified by 4-chloro-l-naphthol appeared as small (at least 30 nm in diameter) electron-dense precipitates. With the anti-TRH serum, deposits were found over all the secretory granules (Fig.  5) . Measurements made on B cells containing at least 30 secretory granules showed that the granule profile diameter varied considerably within a given cell and between different cells, and ranged from 300 to 600 nm; their size distribution is shown in Fig. 6 . The mean value (nanometers±confidence limits, 95%) of the profile diameter was 442±5.04.
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f l o -' . : -VW vations revealed that TRH was found in the B cells characterized by the presence of secretory granules with an electron-opaque paracrystalline core (Fig. 5) . The antigen-antibody complex
The present report is the first description of the development and the location of TRH in the human fetal pancreas. Somewhat surprisingly, high concentrations of TRH are detected during fetal life, particularly between 6 and 8 wk. TRH values then decrease significantly between 9 and 20 wk. The current study also demonstrates that TRH is found in the insulin-containing cells. A major potential problem is the interpretation of these findings with regard to the specificity of the anti-TRH serum.
In the radioimmunoassay, this antiserum cross-reacts with
[3H]TRH (32) . There is no significant reactivity in the TRH assay by other structurally related peptides including TRH free acid (p-Glu-His-Pro NH2), p-Glu-His OH, His-Pro OH, lysinevasopressin, gonadoliberin and somatostatin (32) .2 The control of specificity of the immunocytochemical reaction established that the anti-TRH serum reacted with the TRH molecule, and had no affinity to the heterologous antigens (pancreatic or brain peptides). Also, the staining of B cells by this antiserum was unaffected by incubation with TRH-degradation products. These results are in agreement with our previous study of cells storing TRH and insulin in the adult rat pancreas (17) . The combined use of immunocytochemistry and radioimmunoassay proves to be an invaluable tool for a complete study of the ontogenesis of TRH. The first technique, however, is inevitably dependent on the procedures for tissue preparation. The antigenicity of TRH is not well preserved after immersion in the conventional liquid fixatives (e.g., Bouin-Hollande sublimate, p-formaldehyde, or osmium tetroxide). In contrast, a mixture ofp-formaldehyde and glutaraldehyde followed by a secondary fixation with osmium tetroxide are excellent for preserving the TRH immunoreactivity in the human fetal pancreas. Similar results have been obtained in the adult rat pancreas (17) .
TRH is found in the B cells ofthe islets and possibly coexists with insulin in the same secretory granules. Coexistence of peptides in pancreatic endocrine cells can generally be explained by the fact that they arise from the same precursor. Thus, there are reports of glicentin-and gastric inhibitory polypeptide-like immunoreactants in the pancreatic A cells producing glucagon in human fetus (20, 21, 35, 36 Ontogenesis and ultrastructural feature4 viously been examined in the human fetal p (differentiated) endocrine cells are present di (10-1 1 wk) of gestation, and the morpholc are strongly suggestive of B cells (43) . By ra has been documented that insulin syntht present at 14 wk (44) . In this study, howeve of immunoreactive insulin was not determ nocytological techniques, in contrast, it ha insulin-containing cells are present from 1' methods for determining the age of the fet slight variations, there is good agreement date" of insulin and the data obtained by niques. In this context, it would be of int4 TRH precedes insulin in the developmen cell. Although our data do not allow any ( TRH and insulin ontogenesis, note that in: extract of the pancreas of a 9-wk-old fetus our radioimmunological findings seem to may arise earlier than insulin. 
